RxDoctor Payments Data

John Jefferies

Advanced Heart Failure and Transplant Cardiology · Memphis, TNNPI 1619920469

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Nuwellis, Inc. at 50.0% of the total. Reporting peaked in 2023 at $254,821 and has fallen 78.3% since, to $55,385 in 2025. Among advanced heart failure and transplant cardiology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$719,612in general payments, 2019–2025

Across 549 payments — averaging $1310.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nuwellis, Inc.$360K
  • Sanofi$138K
  • E.r. Squibb & Sons, L.L.C.$62K
  • Amicus Therapeutics, Inc.$39K
  • NS Pharma, Inc.$32K
  • Daxor Corporation$18K
  • plus $72K from 27 others
$732,706in research payments, 2019–2025

Across 93 payments — averaging $7878.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$522K
  • E.r. Squibb & Sons, L.L.C.$58K
  • Novartis$56K
  • Abbott$53K
  • Medtronic$18K
  • Endologix LLC$7K
  • plus $20K from 5 others

What the payments were for

  • Consulting fees$302,08842%
  • Speaking & faculty fees$334,49746%
  • Travel & lodging$49,1917%
  • Food & beverage$33,7975%
  • Education$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nuwellis, Inc.75$359,973
Sanofi91$137,784
E.r. Squibb & Sons, L.L.C.48$61,552
Amicus Therapeutics, Inc.38$39,054
NS Pharma, Inc.45$31,610
Daxor Corporation29$18,103
Medtronic(3 entities)93$17,092
Pfizer15$16,136
Chiesi USA, Inc.9$13,706
Abbott45$6,188
Cvrx, Inc.14$5,869
Myocardial Solutions, Inc.2$5,028
Takeda Pharmaceuticals U.S.A., Inc.1$3,502
AstraZeneca3$1,117
Bioverativ Therapeutics Inc.1$613
Orpyx Medical Technologies Inc.1$400
Elucent Medical11$328
Bristol Myers Squibb1$300
Johnson & Johnson4$248
Bayer3$217
Janssen Scientific Affairs, LLC2$171
Bardy Diagnostics, Inc.1$125
Akcea Therapeutics, Inc.2$112
Alnylam Pharmaceuticals Inc.4$90
Vivaquant Inc, Dba Rhythm Express2$64
Novartis2$60
Novo Nordisk1$38
Sanofi-aventis U.S. LLC1$31
Mallinckrodt Hospital Products Inc.1$23
Lilly USA, LLC1$22
Tolmar Pharmaceuticals, Inc.1$21
Amgen1$17
Boston Scientific1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$719,612 in reported general payments places this provider in the 95th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.

See all advanced heart failure and transplant cardiology providers in Tennessee

Other advanced heart failure and transplant cardiology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →